Clinical trial · Interventional
Breast Cancer PSMA PET
Evaluation of PSMA Expression in Triple Negative Breast Cancer Patients Using 18 F-DCFPyL-PET/CT
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Triple Negative Breast Cancer | Triple-Negative Breast Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PET imaging | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- PET Imaging of breast cancer patients
- description
- Triple negative breast cancer patients will undergo FDG PET/CT and Pyl PET/Ct
- interventionNames
- Diagnostic Test: PET imaging
Primary outcomes (1)
- measure
- Lesion detection sensitivity analysis
- timeFrame
- 4 weeks
- description
- Comparing the sensitivity of 18 F-DCFPyL-PET/CT and FDG PET/CT in metastatic lesion detection in triple-negative breast cancer patients.
Secondary outcomes (1)
- measure
- Quantitative radiotracer uptake analysis
- timeFrame
- 4 weeks
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 90 Years
Show eligibility criteria text
Inclusion Criteria: * Female \>= 18 years of age * Patients in distantly metastatic TNBC based on the initial diagnosis biopsy. * Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included. Exclusion Criteria: * Patients with known active other malignancy. * Unable to tolerate PET/CT procedure. * Pregnant or breastfeeding. * Patients with any medical condition that might compromise the safety of subject during PET acquisitions.
References
Publications (0)
Data not yet available